The U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of Celltrion’s AVTOZMA (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA IV in the United States. “We are proud that AVTOZMA IV has now achieved full indication alignm...